Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00753935 · ClinicalTrials.gov registry record · Early Phase 1

Aspirin Resistance in Coronary Artery Disease

A Early Phase 1 study of Coronary Artery Disease, sponsored by Vanderbilt University.

Completed
Registry status
Early Phase 1
Development phase
92
Enrollment target
1
Study location

NCT00753935: Completed Early Phase 1 study of Coronary Artery Disease, sponsored by Vanderbilt University.

NCT00753935 is a Early Phase 1 study of Coronary Artery Disease that has completed, run by Vanderbilt University. The registered enrollment target is 92 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00753935, a Early Phase 1 study of Coronary Artery Disease, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
Early Phase 1
Development phase
92 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate possible mechanisms of aspirin resistance at a molecular level in aspirin-treated patients with coronary artery disease. We hypothesize that certain patient characteristics associate with aspirin resistance. In addition, we will compare the effects of enteric-coated aspirin and chewable aspirin.

Primary Outcome

Thromboxane A2, the major product of cyclooxygenase cytochrome oxidase (COX-1) in platelets, induces platelet aggregation. Thromboxane B2 is an inactive metabolite/product of thromboxane A2. This primary outcome measures the extent of inhibition of platelet COX-1 by measuring the amount of the metabolite thromboxane B2 in serum.

Conditions Studied

Coronary Artery Disease

Interventions

  • DRUG enteric-coated aspirin
  • DRUG Chewable aspirin

Study Locations (1)

Tennessee

  • Vanderbilt University - Nashville

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2006-06
Est. Completion 2014-03
Phase Early Phase 1
Vanderbilt University

430 total trials

What the finished NCT00753935 record still lists

NCT00753935 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which enteric-coated aspirin is the first listed.

NCT00753935 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT00753935 about?

NCT00753935 is a clinical study titled "Aspirin Resistance in Coronary Artery Disease". The purpose of this study is to evaluate possible mechanisms of aspirin resistance at a molecular level in aspirin-treated patients with coronary artery disease. We hypothesize that certain patient characteristics associate with aspirin resistance. In addition, we will compare the effects of enteric...

What is the current status of trial NCT00753935?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 92 participants. The study started on 2006-06. Estimated completion is 2014-03.

What conditions does trial NCT00753935 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT00753935?

The interventions under investigation include: enteric-coated aspirin (DRUG), Chewable aspirin (DRUG).

Who is sponsoring clinical trial NCT00753935?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00753935 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00753935's enrollment target sits among peer trials

92 154th of 219 higher than 66 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03184545 · 92 participants · Phase 3

    Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome

  • NCT04172532 · 92 participants · Phase 1

    Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

  • NCT04508088 · 92 participants

    Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

  • NCT04840602 · 92 participants · Phase 2

    Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00753935, the US trial registry maintained by the National Library of Medicine. NCT00753935 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.